Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
New York, USA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- DPP1 Inhibitor Market Set to Reach New Heights in the Coming Decade | DelveInsight The DPP1 inhibitor market is experiencing significant growth,...
-
Wilmington, Delaware, Transparency Market Research Inc., Dec. 02, 2024 (GLOBE NEWSWIRE) -- With a market valued at US$ 332.5 million in 2023, the nephropathic cystinosis treatment market (mercado de...
-
Data from Eloxx’s proof-of-concept trial in patients with nonsense mutation Alport Syndrome (NMAS) presented in late-breaking presentation at American Society of Nephrology (ASN) Kidney Week New...
-
First two subjects dosed in Phase 1 clinical trial of ZKN-013; ZKN-013 is being developed for the potential treatment of rare dermatological and other diseases associated with nonsense mutations ...
-
ELX-02 Granted Orphan Drug Designation (ODD) from U.S. Food and Drug Administration (FDA) for Treatment of Alport Syndrome Pre-Investigational New Drug (IND) Meeting Requested with U.S. FDA for...
-
Dublin, April 11, 2024 (GLOBE NEWSWIRE) -- The "Alport Syndrome - Pipeline Insight, 2024" has been added to ResearchAndMarkets.com's offering.The "Alport Syndrome - Pipeline Insight, 2024," report...
-
NEW YORK,, March 20, 2024 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock and warrants of Latch, Inc. Latch, Inc.’s securities were suspended on...
-
Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the treatment of rare dermatological and other diseases associated with nonsense mutationsZKN-013 is a phase I ready...
-
Kidney morphology improved in all three patients with protein re-expression consistent with disease regression in its Phase 2 open-label clinical trial of ELX-02 for the treatment of Alport Syndrome ...
-
ELX-02 treatment improved podocyte foot process effacement in all three patients by an average of 60% based on a blinded kidney biopsy analysis by NIPOKA GmbH Biopsy results support clinical benefit...